Status:
UNKNOWN
Effect of tDCS of the Motor Cortex on Chemotherapy Induced Nausia and Vomiting
Lead Sponsor:
Shereen Mamdouh
Conditions:
Chemotherapy-induced Nausea and Vomiting
Eligibility:
FEMALE
20-60 years
Phase:
NA
Brief Summary
this work is looking for the effect of tDCS of the motor cortex on the chemotherapy induced nausea and vomiting in cancer breast patients
Detailed Description
Chemotherapy has played an important role in improving patient outcomes in oncology and is a cornerstone of therapy for most patients with cancer. Of the adverse effects, none is more feared than chem...
Eligibility Criteria
Inclusion
- breast cancer therapy receiving anthracyclin based adjuvant chemotherapy and prophylaxis against nausea and vomiting
Exclusion
- patients with intracranial metallic devices or with pacemakers or any other device.
- patients with extensive myocardial ischemia
- patients known to have epilepsy patients refusal.
Key Trial Info
Start Date :
January 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2019
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT03405324
Start Date
January 1 2018
End Date
September 1 2019
Last Update
June 28 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
South Egypt Cancer Institute
Asyut, Egypt, 11715